Stockreport

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

Madrigal Pharmaceuticals, Inc.  (MDGL) 
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am Check Earnings Report
US:NASDAQ Investor Relations: madrigalpharma.com
PDF Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at h [Read more]